Clinical-stage biopharmaceutical company GH Research (NASDAQ:GHRS) priced of its previously announced underwritten public offering in the U.S. of 10M ordinary shares at a public…
tupungato/iStock via Getty ImagesRAPT Therapeutics (NASDAQ:RAPT) stock rallied as much as 180% Monday after the company announced a worldwide licensing…